Publications-abstracts

NovellusDx is proud to support the clinical and academic communities. If you would like to collaborate on your research, please contact us directly.

Retrospective analysis of a SHIVA01 trial cohort using functional mutational analysis
successfully predicted treatment outcome

ESMO (EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY) 2017 congress

Gabi Tarcic2, Maud Kamal1, Sylvain Dureau3, Oded Edelheit2, Zohar Barbash2, Charlotte Lecerf1, Claire Morel1, Benjamin Miron2, Ori Zelichov2, Celine Callens4, Nicolas Servant5, Ivan Bieche4, Michael Vidne2, Christophe Le Tourneau1,5

1. Institut Curie, Paris & Saint-Cloud, France – Department of Medical Oncology
2. NovellusDx, Jerusalem, Israel
3. Institut Curie, Paris & Saint-Cloud, France – Department of Biostatistics
4. Institut Curie, Paris & Saint-Cloud, France – Department of Genetics
5. Institut Curie, Paris & Saint-Cloud, France – Department of INSERM U900

 

 

 

 

 

A Novel High-Throughput Multispectral Cell Segmentation Algorithm

MIUA: Annual Conference on Medical Image Understanding and Analysis 2017

Jenia Golsbtein, Yaniv Tocker, Revital Sharivkin, Gabi Tarcic, and Michael Vidne

 

Not all RAS Mutations Created Equal: Functional and Clinical Characterization of 80 Different KRAS/NRAS Mutations

ASCO Annual Meeting 2017

Jonathan M. Loree1, Benjamin Miron5, Vijaykumar Holla2, Michael J. Overman1, Allan A. Pereira1, Michael Lam1, Van K. Morris1, Kanwal PS Raghav1, Mark J. Routbort3, Kenna Shaw2, Nitza Burck5, Revital Sharivkin5, Oded Edelheit5, Funda Meric-Bernstam4, Michael Vidne5, Gabi Tarcic5, Scott Kopetz1
1. MD Anderson Department of Gastrointestinal Medical Oncology
2. MD Anderson Departments Zayed Institute for Personalized Cancer Therapy
3. MD Anderson Department of Pathology
4. MD Anderson Department of Investigational Cancer Therapeutics
5. NovellusDx, Jerusalem, Israel

 

 

Novel Platform to Profile Variants of Uncertain Significant (VUS) with Preliminary Retrospective Clinical Validation in Non-Small Cell Lung Cancer (NSCLC)

AACR Annual Meeting 2017

Benjamin Miron1, Gabi Tarcic1, Oded Edelheit1, Nitza Burck1, Michael Vidne1, Laila Roisman2, Nir Peled2

1. NovellusDx, Jerusalem, IL,

2. Davidoff Cancer Center, Petah Tikvah, IL

Sub-Clonal Therapy by two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-mutated Lung Cancer

Journal of Thoracic Oncology, 2017

Nir Peled, MD, PhD1, 2, Laila C. Roisman, PhD1, Benjamin Miron, MD3, Raphael Pfeffer, MD4, Richard B. Lanman, MD5, Maya Ilouse, PhD1, Addie Dvir6, Lior Soussan-Gutman6, Fabrice Barlesi, MD, PhD7, Gabi Tarcic, PhD3, Oded Edelheit, PhD3, David Gandara, MD8, Yehiel Elkabetz, PhD9

  1. Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel
  2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  3. NovellusDx, Jerusalem, Israel
  4. Assuta Medical Center, Tel Aviv, Israel
  5. Guardant Health, Inc., Redwood City, CA, USA
  6. Oncotest, Teva Pharmaceutical Industries Ltd., Shoam, Israel
  7. Aix Marseille University; Assistance Publique Hôpitaux de Marseille. Multidisciplinary Oncology & Therapeutic Innovations Dept. Marseille, France
  8. University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
  9. Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel

Phase 1B Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation

Cancer Discovery, 2016

David S. Hong1,*, Van K. Morris2, Badi El Osta3, Alexey V. Sorokin2, Filip Janku1, Siqing Fu1, Michael J. Overman2, Sarina Piha-Paul1, Vivek Subbiah1, Bryan Kee2, Apostolia Tsimberidou1, David Fogelman2, Jorge Bellido1, Imad Shureiqi2, Helen Huang1, Johnique Atkins1, Gabi Tarcic4, Nicolas Sommer5, Richard Lanman6, Funda Meric-Bernstam1 and Scott Kopetz2

  1. Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
  2. Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
  3. Medical Oncology, Emory University School of Medicine
  4. NovellusDX
  5. Genentech
  6. Guardant Health

Functional mutational analysis to assess the oncogenic activity of variant of uncertain significance detected in patients enrolled in the SHIVA trial

EORTC-NCI-AACR, 2016

G. Tarcic1, M. Kamal2, O. Edelheit1, Z. Barbash1, M. Vidne1, B. Miron1, C. Callens2, N. Servant2, I. Bieche2, C. LeTourneau2

  1. NovellusDx, Jerusalem, Israel
  2. Institut Curie, Paris, France

Functional profiling of oncogenic mutations in lung cancer patients (NCT02274025) – interim results

ESMO Annual Meeting, 2016

B. Miron1, N. Peled2, G. Tarcic1, Z. Barbash1, O. Edelheit1, M. Vidne1, M.R. Kramer3

  1. R&D, NovellusDx, Jerusalem, Israel,
  2. Thoracic Cancer Unit, Davidoff Cancer Center, Petach Tiqwa, Israel,
  3. Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel

Functional characterization of variants of unknown significance (VUS) in patients and their responsiveness to targeted therapy drugs (TTD)

ESMO Annual Meeting, 2016

G. Tarcic1, C.M. Walko2, H.L. McLeod2, J.K. Hicks2, Z. Barbash1, O. Edelheit1, B. Miron1, M. Vidne1, E. Padron2

  1. NovellusDx, Jerusalem, Israel
  2. Malignant Hematology, H. Lee Moffitt Cancer Center University of South Florida, Tampa, FL, USA

Functional characterization of mutations and their interaction using the novel functional annotation for cancer treatment (FACT) platform

ESMO Annual Meeting, 2016

B. Miron1, N. Peled2, Z. Barbash1, O. Edelheit1, M. Vidne1, R. Sharivkin1 and G. Tarcic1

  1. NovellusDx, Jerusalem, Israel
  2. Thoracic Cancer Unit, Davidoff Cancer Center, Petach Tiqwa, Israel

Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram).

ASCO Annual Meeting, 2016

R. J. Sullivan1, Z. Barbash2, O. Edelheit2, M. Vidne2, J. A. Sosman3, K. Flaherty1, M. A. Davies4, D. B. Johnson3, G. Tarcic2

  1. Massachusetts General Hospital, Boston, MA
  2. NovellusDx, Jerusalem, Israel; Novellusdx, Jerusalem, Israel
  3. Vanderbilt-Ingram Cancer Center, Nashville, TN
  4. Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston, MA
  5. The University of Texas MD Anderson Cancer Center, Houston, TX
  6. Vanderbilt University, Nashville, TN

Functional characterization of VUS mutations found in patients’ cellfree circulating tumor DNA (ctDNA) using Precision Cancer Analysis System (PCAS)

ASCO Annual Meeting, 2016

G. Tarcic1, D. A. Simon2, M. Jacobstein2, R. B. Lanman2, M. Vidne1, Z. Barbash1, O. Edelheit1, A. Talasaz2;

  1. NovellusDx, Jerusalem, Israel
  2. Guardant Health, Redwood City, CA

Identification of the functional significance of mutations using the novel Precision Cancer Analysis System.

ASCO Annual Meeting, 2015

N. Peled1, Z. Barbash2, N. Barabash-Katzir2, H. Nevo2, M. Vidne2, M. Adamek3, M. R. Kramer4, N. Goncharenko5, Y. Fellig6, K. Meir6, G. Tarcic2;

  1. Davidoff Cancer Center, Petach Tiqwa, Israel
  2. NovellusDx, Jerusalem, Israel
  3. Medical University of Silesia, Zabrze, Poland
  4. Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
  5. IBBL (Integrated BioBank of Luxembourg), Luxembourg, Luxembourg
  6. Hadassah-Hebrew-University-Medical-Cente, Jerusalem, Israel